Short-term Investigation of Resveratrol on Lipid Turnover in Morbidly Obese Women Undergoing Gastric Bypass Surgery. Effects on Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism and Liver VLDL-triglyceride Uptake.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Resveratrol (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 30 Jan 2014 Biomarkers information updated
- 29 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.